Back to top
more

Reata Pharmaceuticals, Inc. (RETA)

(Delayed Data from NSDQ)

$80.41 USD

80.41
117,440

+2.31 (2.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $80.37 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y

by Zacks Equity Research

Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.

Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q4 Earnings Expected to Decline

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reata (RETA) Falls on Negative Advisory Committee Outcome

by Zacks Equity Research

An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.

Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug

by Zacks Equity Research

The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.

Do Options Traders Know Something About Reata (RETA) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Reata (RETA) stock based on the movements in the options market lately.

Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat

by Zacks Equity Research

Reata (RETA) beats estimates for earnings and sales. An advisory committee meeting is scheduled on Dec 8 to discuss bardoxolone NDA.

Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 15.09% and 427.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reata (RETA) Confirms Omaveloxolone NDA Filing in Q1 2022

by Zacks Equity Research

Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its pre-NDA meeting with the FDA.

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 12.2% Since Last Earnings Report?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Reata (RETA) beats estimates for earnings and sales. Stock down on negative regulatory update on lead pipeline candidate, bardoxolone.

    Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 6.10% and 53.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Reata Pharmaceuticals, Inc. (RETA) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock?

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    Reata (RETA) Soars on Potential Omaveloxolone NDA Filing

    by Zacks Equity Research

    The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.

    Company News for May 20, 2021

    by Zacks Equity Research

    Companies In The News Are: TGT, AMD, AZN, RETA

    Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss

    by Zacks Equity Research

    Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.

    Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 14.68% and -32.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q1 Earnings Expected to Decline

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Strength Seen in Reata Pharmaceuticals, Inc. (RETA): Can Its 3% Jump Turn into More Strength?

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

    by Zacks Equity Research

    Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

    Reata Pharmaceuticals, Inc. (RETA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Reata (RETA) Omaveloxolone Program Faces Delay on FDA Update

    by Zacks Equity Research

    Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.

    Reata Pharmaceuticals, Inc. (RETA) Down 6.2% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.